Related News
Home 禄 Business 禄 Manufacturing
Boehringer Ingelheim agrees to R&D joint venture in Shanghai
By Ding Yining |
June 6, 2013, Thursday
|
Online Edition
Online Edition
GERMAN pharmaceutical maker Boehringer Ingelheim said today it has teamed with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co Ltd to build a 500 million yuan (US$80.6 billion) biopharmaceutical R&D and manufacturing facility.
Boehringer Ingelheim will invest more than 35 million euros (US$45.8 million) in the first phase facility, which is expected to be operational by early 2016.
Zhangjiang Group will provide 150 million yuan worth of land use permission and factory plants in the first phase. The new site, in Zhangjiang High-tech Park in the Pudong New Area, will provide a full range of development and clinical services to domestic and overseas pharmaceutical companies.
Boehringer Ingelheim will become the first multinational drug maker to provide contract manufacturing services for local firms.
"The contract manufacturing facility is expected to lower production costs for smaller start-up companies and lift their capital pressure, and it will also help boost Shanghai's biopharmaceutical industry," said Wang Lanzhong, General Manager of Shanghai Zhangjiang Biotech Base Development Co Ltd.
"Biopharmaceuticals, together with prescription medicines, consumer health care, animal health and manufacturing will become five pillars driving our business in China," said David Preston, chairman and CEO of Boehringer Ingelheim China and HK.
Boehringer Ingelheim will invest more than 35 million euros (US$45.8 million) in the first phase facility, which is expected to be operational by early 2016.
Zhangjiang Group will provide 150 million yuan worth of land use permission and factory plants in the first phase. The new site, in Zhangjiang High-tech Park in the Pudong New Area, will provide a full range of development and clinical services to domestic and overseas pharmaceutical companies.
Boehringer Ingelheim will become the first multinational drug maker to provide contract manufacturing services for local firms.
"The contract manufacturing facility is expected to lower production costs for smaller start-up companies and lift their capital pressure, and it will also help boost Shanghai's biopharmaceutical industry," said Wang Lanzhong, General Manager of Shanghai Zhangjiang Biotech Base Development Co Ltd.
"Biopharmaceuticals, together with prescription medicines, consumer health care, animal health and manufacturing will become five pillars driving our business in China," said David Preston, chairman and CEO of Boehringer Ingelheim China and HK.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
